Company intelligence / Profile preview

AirNexis Therapeutics

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

AirNexis Therapeutics is a clinical-stage biotechnology company focused on developing therapies for pulmonary diseases. The company launched in January 2026 with $200 million in Series A funding to advance AN01 (HSK39004), a dual PDE3/4 inhibitor in Phase 2 development for the treatment of chronic obstructive pulmonary disease (COPD).

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Haisco Pharmaceutical Group

Beyond the preview

Go deeper on AirNexis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AirNexis Therapeutics.

Explore the full profile